Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights
Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million [Yahoo! Finance]
Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million
Fortress Biotech (FBIO) was downgraded by Zacks Research from "strong-buy" to "hold".
Fortress Biotech's Cyprium enters agreement to sell PRV for $205M [Yahoo! Finance]